GOOD READS

Biocon group net up 51 percent in fiscal 2013

Bangalore, April 26 (IANS) India's biotechnology major Biocon Ltd posted consolidated net profit of Rs.509 crore for fiscal 2012-13, registering a whopping 51 percent year-on-year (YoY) growth over previous fiscal (2011-12) at Rs.338 crore.

In a regulatory filing to the Bombay Stock Exchange (BSE) Friday, the Bangalore-based firm said consolidated income for the fiscal (FY 2013) under review grew 18 percent YoY to Rs.2,538 crore from Rs.2,148 crore year ago.

On standalone basis, the parent company, however, reported a modest eight percent YoY net profit growth of Rs.276 crore from Rs.256 crore year ago and income of Rs.1,989 crore for last fiscal, which is 23 percent up YoY from Rs.1,622 crore year ago.

"Fiscal 2013 closed on a very strong note, with growth driven by research services, branded formulations and bisimilar services, led by generic insulins," Biocon chairperson Kiran Mazumdar Shaw told reporters.

Biopharama business grew 10 percent YoY to Rs.1,523 crore, while branded formulations 34 percent YoY to 347 crore and research services (Syngene & Clinigene) 36 percent YoY to Rs.557 crore.

"Our insulin franchise continues to garner market share across India and emerging markets and accounts for 10 percent of our sales," Shaw said.

The company extended partenership with the US-based specialty pharma firm Mylan by re-licensing its generic insulins and thereby reducing development costs involved in global commercialisation.

"Looking ahead, we intend to sustain the growth momentum by optimising small molecules portfolio, expanding insulin footprint in emerging markets and continuing to deliver robust growth in branded formulations and research services," Shaw asserted.

The company received $200 million (Rs.1,100 crore) from Mylan as an upfront for further development of generic insulins.

For fourth quarter (January-March), total revenue grew only four percent YoY to Rs.649 crore from Rs.622 crore year ago, but declined two percent sequentially from Rs.660 crore posted in October-December of fiscal under review.

Net profit for fourth quarter (Q4), however, shot up 170 percent sequentially to Rs.249 crore from Rs.92 crore in third quarter (Q3) and 154 percent YoY from Rs.98 crore in like quarter year ago.

Though operating margin or earnings before interest, depreciation and amortization (Ebitda) increased three percent YoY to Rs.596 crore from Rs.578 crore year ago, it declined sequentially 26 percent to Rs.124 crore in fourth quarter (Q4) from Rs.167 crore in third quarter (Q3) and 21 percent YoY from Rs.156 crore in same quarter year ago.

The company's board of directors recommended 100 percent dividend of Rs.5 per share and 50 percent special dividend of Rs.2.50 per share in pursuant to the re-licensing of its insulin analogs portfolio.

Quiz: How well do you know India's economy?

Question 1

Which of these products is India the world's largest producer of?

Poll Choice Options
  • Wheat
  • Rice
  • Milk
1
2
3
4
5
6
7
8
9
10

Latest News

IN-DEPTH ANALYSIS & INTERVIEWS

  • This might well be India’s biggest Ponzi scam

    It was just too good to be true. Ashok Khital, 45, displays every symptom of a man who knows he's been conned. …

  • India's star studded football league

    High and mighty including Sachin, Salman & Sun Group buy ISL teams …

  • Leaderspeak with Rajesh Janey

    Rajesh Janey, President - India & SAARC, EMC shares many firsts in his life. …

  • Power Hungry

    Gujarat has power round-the-clock. Most other states do not. Why this will matter in the general elections. …

  • Etcetera

    The most keenly watched contest of the current general election will be the one for the Varanasi parliamentary seat, where the Bharatiya Janata Party's prime ministerial hopeful Narendra Modi squares off ... …

  • Economy vs Democracy

    As the country gets election fever, cash comes out of mattresses and turns into liquor, gifts, and food. But it is not bad for the health of the economy, reports Sarika Malhotra from the trenches. …

  • Bracing for Challenges

    Raghuram Rajan is preparing to deal with concerns that may arise when a new government takes charge. …

MARKET MOVERS

  • Most Actives
    Most Actives
    NamePriceChange% Chg
    52.80+5.15+10.81%
    HCLINFO.BO
    16.20-0.32-1.94%
    UNITECH.BO
    14.25+0.89+6.66%
    SUZLON.BO
    21.20+3.05+16.80%
    HOTELEELA.BO
    200.75+8.15+4.23%
    SSLT.BO
  • Price % Gainers
    Price % Gainers
    NamePriceChange% Chg
    105.30+17.55+20.00%
    SHASUNPHA.BO
    79.85+13.30+19.98%
    JUBLIND.BO
    15.51+2.58+19.95%
    HIMIN.BO
    19.85+3.30+19.94%
    ORIENTP.BO
    29.90+4.95+19.84%
    SOMICONV.BO
  • Price % Losers
    Price % Losers
    NamePriceChange% Chg
    -11.50-100.00%
    4THGEN.BO
    -17.30-100.00%
    ALFAICA.BO
    -15.25-100.00%
    AMAL.BO
    -10.65-100.00%
    BORAX.BO
    -31.00-100.00%
    BRADYM.BO
  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.